Sandy Amorim

1.3k total citations · 1 hit paper
20 papers, 815 citations indexed

About

Sandy Amorim is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Sandy Amorim has authored 20 papers receiving a total of 815 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 6 papers in Neurology. Recurrent topics in Sandy Amorim's work include Lymphoma Diagnosis and Treatment (11 papers), CNS Lymphoma Diagnosis and Treatment (6 papers) and Viral-associated cancers and disorders (5 papers). Sandy Amorim is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), CNS Lymphoma Diagnosis and Treatment (6 papers) and Viral-associated cancers and disorders (5 papers). Sandy Amorim collaborates with scholars based in France, United States and United Kingdom. Sandy Amorim's co-authors include Catherine Thiéblemont, Franck Morschhauser, Emanuele Zucca, David Cunningham, Lionel Karlin, Mary Gleeson, Patrice Herait, Florence Broussais, Thierry Façon and Anastasios Stathis and has published in prestigious journals such as Blood, The Lancet Oncology and European Journal of Cancer.

In The Last Decade

Sandy Amorim

19 papers receiving 804 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

2016 328 citations Sandy Amorim, Anastasios Stathis et al. The Lancet Haematology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandy Amorim France	9	406	368	288	253	197	20	815
Beata Holkova United States	13	297 0.7×	222 0.6×	307 1.1×	139 0.5×	155 0.8×	48	634
Ka Lung Wu Belgium	14	232 0.6×	287 0.8×	361 1.3×	210 0.8×	344 1.7×	39	708
JL Huret France	6	301 0.7×	126 0.3×	166 0.6×	128 0.5×	154 0.8×	100	521
Wyndham H. Wilson United States	4	250 0.6×	340 0.9×	245 0.9×	95 0.4×	69 0.4×	7	647
Gottfried von Keudell United States	13	293 0.7×	179 0.5×	243 0.8×	151 0.6×	47 0.2×	46	560
Fontanet Bijou France	11	234 0.6×	117 0.3×	233 0.8×	217 0.9×	131 0.7×	46	467
Maria Delioukina United States	13	426 1.0×	157 0.4×	308 1.1×	168 0.7×	63 0.3×	33	652
Martin Dreyling Germany	13	470 1.2×	89 0.2×	344 1.2×	226 0.9×	50 0.3×	28	622
Emanuele Cencini Italy	13	281 0.7×	108 0.3×	164 0.6×	262 1.0×	103 0.5×	55	535
Haiwen Huang China	11	203 0.5×	154 0.4×	234 0.8×	122 0.5×	100 0.5×	43	491

Countries citing papers authored by Sandy Amorim

Since Specialization

Citations

This map shows the geographic impact of Sandy Amorim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandy Amorim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandy Amorim more than expected).

Fields of papers citing papers by Sandy Amorim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandy Amorim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandy Amorim. The network helps show where Sandy Amorim may publish in the future.

Co-authorship network of co-authors of Sandy Amorim

This figure shows the co-authorship network connecting the top 25 collaborators of Sandy Amorim. A scholar is included among the top collaborators of Sandy Amorim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandy Amorim. Sandy Amorim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Amorim, Sandy, et al.. (2024). Combination of CD20xCD3 Bispecific Antibodies with Ibrutinib and Lenalidomide Shows Efficacy in Relapsed/ Refractory CNS Lymphoma. Blood. 144(Supplement 1). 6453–6453.

Josseaume, Nathalie, Quentin Riller, Claire Deligne, et al.. (2019). Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. Cancer Immunology Immunotherapy. 68(10). 1561–1572. 2 indexed citations

Cornillon, Jérôme, Élisabeth Daguenet, Jacques‐Olivier Bay, et al.. (2019). BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Annals of Hematology. 98(8). 1973–1980. 1 indexed citations

Deau, Bénédicte, Sandy Amorim, Aurore Perrot, et al.. (2018). Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study. British Journal of Haematology. 181(3). 341–349. 7 indexed citations

Dumas, Guillaume, Lucie Biard, Sandy Amorim, et al.. (2018). Intensive care unit admission in patients with T cell lymphomas: clinical features and outcome. Annals of Hematology. 98(1). 195–203. 4 indexed citations

Morel, Alexandre, Josette Brière, Laurence Lamant, et al.. (2017). Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study. European Journal of Cancer. 83. 146–153. 15 indexed citations

Canouï, Étienne, Julien Loubinoux, Sandrine Valade, et al.. (2017). The value of molecular techniques to diagnose Ureaplasma urealyticum and Nocardia farcinica pleuropneumonia in a patient with diffuse large B-cell lymphoma. International Journal of Infectious Diseases. 64. 93–95. 12 indexed citations

Amorim, Sandy, Anastasios Stathis, Mary Gleeson, et al.. (2016). Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. The Lancet Haematology. 3(4). e196–e204. 328 indexed citations breakdown →

Gac, Anne‐Claire, Nabih Azar, Étienne Daguindau, et al.. (2016). Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases. Leukemia & lymphoma. 57(5). 1149–1153. 3 indexed citations

10.

Margerie‐Mellon, Constance de, C. de Bazelaire, Sandy Amorim, et al.. (2015). Diagnostic Yield and Safety of Computed Tomography–guided Mediastinal Core Needle Biopsies. Journal of Thoracic Imaging. 30(5). 319–327. 18 indexed citations

11.

Amorim, Sandy, et al.. (2015). Clinical features of life-threatening complications following autologous stem cell transplantation in patients with lymphoma. Leukemia & lymphoma. 56(11). 3090–3095. 7 indexed citations

12.

Dupuis, Jehan, Franck Morschhauser, Hervé Ghesquières, et al.. (2015). Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. The Lancet Haematology. 2(4). e160–e165. 81 indexed citations

13.

Garciaz, Sylvain, Stéphanie Harel, Sandy Amorim, et al.. (2015). Rituximab‐ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. British Journal of Haematology. 175(4). 735–737. 6 indexed citations

14.

Bernard, Sophie, Lauriane Goldwirt, Sandy Amorim, et al.. (2015). Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 126(14). 1695–1698. 106 indexed citations

15.

Faguer, Stanislas, Virginie Lemiale, Étienne Lengliné, et al.. (2014). Outcomes after intensive care unit admission of patients with newly diagnosed lymphoma. Leukemia & lymphoma. 56(5). 1240–1245. 14 indexed citations

16.

Younes, Anas, Catherine Thiéblemont, Franck Morschhauser, et al.. (2014). Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. The Lancet Oncology. 15(9). 1019–1026. 186 indexed citations

17.

Fleury, Isabelle, Sandy Amorim, Nicolas Mounier, et al.. (2014). Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. Leukemia & lymphoma. 56(7). 2025–2031. 4 indexed citations

18.

Dupuis, Jehan, Franck Morschhauser, Hervé Ghesquières, et al.. (2014). Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL). Blood. 124(21). 504–504. 11 indexed citations

19.

Thiéblemont, Catherine, Anastasios Stathis, Giorgio Inghirami, et al.. (2014). A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. Blood. 124(21). 4417–4417. 6 indexed citations

20.

Bernard, Sophie, Lauriane Goldwirt, Sandy Amorim, et al.. (2014). Promising Results of Ibrutinib in Three Patients with Secondary Central Nervous System Mantle Cell Lymphoma. Blood. 124(21). 3105–3105. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact